Your browser doesn't support javascript.
loading
Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study.
Serra-Bellver, Patricio; Versluis, Judith M; Oberoi, Honey K; Zhou, Cong; Slattery, Timothy D; Khan, Yasir; Patrinely, James R; Pires da Silva, Inês; Martínez-Vila, C; Cook, Natalie; Graham, Donna M; Carlino, Matteo S; Menzies, Alexander M; Arance, Ana M; Johnson, Douglas B; Long, Georgina V; Pickering, Lisa; Larkin, James M G; Blank, Christian U; Lorigan, Paul.
Afiliação
  • Serra-Bellver P; Department of Medical Oncology, Christie NHS Foundation Trust, Manchester, United Kingdom. Electronic address: p.serra@nhs.net.
  • Versluis JM; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Oberoi HK; Department of Medical Oncology, Christie NHS Foundation Trust, Manchester, United Kingdom; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain.
  • Zhou C; Cancer Research UK Manchester Institute Cancer Biomarker Centre, University of Manchester, United Kingdom.
  • Slattery TD; Department of Medical Oncology, Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Khan Y; Department of Medical Oncology, Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Patrinely JR; Department of Medical Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Pires da Silva I; Melanoma Institute Australia, The University of Sydney and the Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Department of Medical Oncology, Westmead and Blacktown Hospital, Sydney, Australia.
  • Martínez-Vila C; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain.
  • Cook N; Department of Medical Oncology, Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, University of Manchester, United Kingdom.
  • Graham DM; Department of Medical Oncology, Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, University of Manchester, United Kingdom.
  • Carlino MS; Melanoma Institute Australia, The University of Sydney and the Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Department of Medical Oncology, Westmead and Blacktown Hospital, Sydney, Australia.
  • Menzies AM; Melanoma Institute Australia, The University of Sydney and the Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, Australia.
  • Arance AM; Institut D'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.
  • Johnson DB; Department of Medical Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Long GV; Melanoma Institute Australia, The University of Sydney and the Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, Australia.
  • Pickering L; Department of Medical Oncology, Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Larkin JMG; Department of Medical Oncology, Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Blank CU; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Lorigan P; Department of Medical Oncology, Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, University of Manchester, United Kingdom.
Eur J Cancer ; 176: 121-132, 2022 11.
Article em En | MEDLINE | ID: mdl-36215945
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Melanoma Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Melanoma Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article